Surging nuclear orders tempered by profit margin reset
- Q3 2026 backlog reached a record $1.25 billion as nuclear power demand accelerated.
- Total revenue grew 24.5% to $277.8 million, with organic growth picking up to 6.5%.
- Management withdrew their 2028 margin target to fund AI and cybersecurity investments.
- Nuclear power orders more than doubled organically, driven by plant life extensions.
- The Medical segment saw margin expansion despite a sluggish broader market.
Explosive nuclear growth meets profit trade-offs
Mirion is riding a massive wave of nuclear power investment. In Q3 2026, the company reported a record $1.25 billion backlog. Management cited clear demand drivers, including catch-up capital spending, plant life extensions, and digital transformation. Total revenue grew 24.5% year over year to $277.8 million. Nuclear power orders grew 105% organically, cementing the company as a key supplier for the industry.
The bull case focuses on this unprecedented revenue visibility. Mirion is becoming a default partner in the small modular reactor race, securing $54 million in year-to-date orders across 11 different reactor designers. Proposed regulatory rules for 40-year plant life extensions provide decades of further visibility, helping to derisk the company's aggressive growth projections.
The bear case centers on the cost of this growth. Management recently withdrew their 2028 EBITDA margin target of 30%. They chose to sacrifice near-term profits to heavily fund AI and cybersecurity initiatives, while also dealing with slower margin realization from the Paragon acquisition. This margin reset may alienate investors looking for operating leverage, especially since the Medical segment is still dealing with a prolonged sluggish stretch.
Critical tools for regulated customers
Mirion makes money by selling radiation detection, measurement, monitoring, and safety systems. Its customers include nuclear power plants, defense agencies, research labs, hospitals, and cancer-care centers. These buyers care about safety, approvals, and reliability, making it hard for them to switch suppliers.
The business relies on two main types of revenue. One is recurring flow work, such as replacements, service, dosimetry badges, and software tied to a large installed base. The other is larger project work, such as new plant systems, reactor upgrades, and small modular reactor orders. Project work is valuable, but the timing can be uneven.
Paragon and Certrec pushed Mirion deeper into the nuclear plant life cycle. Certrec helps with licensing and regulatory needs. Paragon helps with obsolescence, parts availability, and engineered solutions. That broader offer helps Mirion win more work, but it also raised the cost and risk of integration.
Medical gives the company a second lane. It sells quality assurance tools for radiation therapy, nuclear medicine equipment, dosimetry services, and newer AI software. This segment was a drag on recent growth, so a lasting recovery is essential for overall margin stability.
Radiation tools across two markets
Nuclear detection and monitoring
These systems help nuclear sites detect, measure, and monitor radiation. Demand is rising as utilities extend plant lives and plan new reactor projects.
Paragon engineered nuclear solutions
Paragon adds safety-related systems, replacement parts, and obsolescence support. This business serves large-scale reactors and emerging small modular reactors.
Certrec regulatory compliance
Certrec helps nuclear customers with plant licensing and ongoing regulatory work. This makes Mirion useful earlier in a plant's life cycle.
Defense and research instruments
Mirion sells radiation detection and identification tools to defense, labs, and research customers. This work adds breadth beyond commercial nuclear power.
Radiation Therapy Quality Assurance
RTQA products help make radiation cancer treatment safer and more accurate. New platforms like Daily QA4 Pro aim to boost sluggish hardware sales.
Nuclear medicine and dosimetry
This area includes dose calibrators, software platforms, and personal radiation monitoring services. It supports hospitals and care teams that work around radiation.
AI and oncology software
Mirion is pushing new AI tools like the PlanAI dosimetry platform. These aim to improve workflow, but AI also brings legal, compliance, and competitive risks.
Nuclear remains the primary driver
Segment shares use approximate Q3 2026 revenue from Mirion disclosures, where Nuclear & Safety generated 70% of revenue and Medical generated 30%.
What can break the story
Profit margin expansion stalls
High impact · High oddsManagement withdrew their 2028 margin target to fund AI investments and absorb slower Paragon margin growth. If these heavy investments fail to deliver long-term leverage, profitability will suffer.
Medical segment sluggishness
Medium impact · Medium oddsWhile margins improved slightly, the Medical segment continues to face a prolonged flat spot in demand. If new product launches like PlanAI fail to gain traction, the segment will drag on company-wide growth.
Deals add sales but limit profit
High impact · Medium oddsParagon and Certrec have lifted revenue and orders, but integrating them has pressured operating margins. If synergies arrive slowly or integration causes operational hiccups, the growth story may look expensive.
SMR orders take longer to convert
Medium impact · Medium oddsMirion's growth plan depends in part on small modular reactors, which remain an emerging market. The company has order momentum, but SMR customers still face design, regulatory, financing, and buildout risks.
In one breath
What does Mirion Technologies do?
Mirion sells radiation detection, monitoring, measurement, and safety products. Its main customers are nuclear power plants, defense agencies, research labs, hospitals, and cancer-care providers.
Why is nuclear important to Mirion?
Nuclear and Safety made up roughly 70% of recent revenue. The segment is also where orders are growing fastest after the Paragon and Certrec acquisitions, driven by plant life extensions and digital upgrades.
What is the biggest risk for Mirion stock?
A key risk is that strong nuclear orders fail to translate into high profits due to AI investments and integration costs, or that the Medical segment fails to recover from ongoing sluggish demand.
Is Mirion only a nuclear company?
No. Medical makes up around 30% of revenue and includes radiation therapy quality assurance, nuclear medicine, dosimetry, and oncology software. Still, the company is highly tied to the nuclear industry.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Specialty Industrial Machinery companies
Companies near Mirion Technologies, Inc. in Finn's Specialty Industrial Machinery industry ranking.

